MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
0.7428
+0.0047
+0.64%
After Hours: 0.7200 -0.0228 -3.07% 19:45 12/26 EST
OPEN
0.7270
PREV CLOSE
0.7381
HIGH
0.7450
LOW
0.7048
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
7.29
52 WEEK LOW
0.6400
MARKET CAP
72.78M
P/E (TTM)
-0.8900
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATYR last week (1215-1219)?
Weekly Report · 6d ago
Analysts Conflicted on These Healthcare Names: aTyr Pharma (ATYR) and Novan (NOVN)
TipRanks · 12/17 17:10
Weekly Report: what happened at ATYR last week (1208-1212)?
Weekly Report · 12/15 09:11
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
PR Newswire · 12/09 01:59
aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations
Reuters · 12/08 12:42
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Barchart · 12/08 12:36
Weekly Report: what happened at ATYR last week (1201-1205)?
Weekly Report · 12/08 09:10
aTyr Pharma Receives Nasdaq Deficiency Notice
TipRanks · 12/05 21:38
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.